Wright-Mitchell Jane 4
4 · Vera Therapeutics, Inc. · Filed Mar 25, 2026
Research Summary
AI-generated summary of this filing
Vera Therapeutics CLO Jane Wright-Mitchell Receives Awards
What Happened Jane Wright-Mitchell, Chief Legal Officer of Vera Therapeutics (VERA), received two awards on March 23, 2026: 42,403 restricted stock units (RSUs) and 56,850 derivative shares (stock-option style award), each reported at $0 per share. These were grants under the issuer’s compensation/inducement program rather than open-market purchases or sales.
Key Details
- Transaction date: March 23, 2026. Form 4 filed March 25, 2026 (timely filing).
- Consideration: $0.00 per share for both the 42,403 RSUs and the 56,850 derivative award.
- Shares owned after transaction: Not specified in the filing.
- Footnote F1 (RSUs): 42,403 RSUs granted under the Issuer’s 2024 Inducement Plan. Vesting: one-fourth (rounded) vests on each of May 20, 2027, 2028, 2029 and 2030, subject to continuous service.
- Footnote F2 (derivative/option): 56,850-share derivative award vests 12/48ths on March 23, 2027, then 1/48th monthly thereafter, subject to continuous service.
- Nature of transaction code: A = Award/Grant. No sale or purchase reported; no tax-withholding or disposition shown.
Context These awards are compensation-related grants that vest over multiple years and do not reflect an immediate cash purchase or sale. The derivative entry represents a stock-option–style award with a multi-year vesting schedule; such grants typically align executive incentive/retention rather than indicate near-term trading intent.
Insider Transaction Report
- Award
Class A Common Stock
[F1]2026-03-23+42,403→ 42,403 total - Award
Stock Option (right to buy)
[F2]2026-03-23+56,850→ 56,850 totalExercise: $40.73Exp: 2036-03-22→ Class A Common Stock (56,850 underlying)
Footnotes (2)
- [F1]Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2024 Inducement Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of May 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.
- [F2]12/48ths of the shares subject to the stock option will vest and become exercisable on March 23, 2027, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.